194 related articles for article (PubMed ID: 34844609)
1. Infection with SARS-CoV-2 causes flares in patients with juvenile idiopathic arthritis in remission or inactive disease on medication.
Hügle B; Krumrey-Langkammerer M; Haas JP
Pediatr Rheumatol Online J; 2021 Nov; 19(1):163. PubMed ID: 34844609
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 vaccine safety in adolescents with inflammatory rheumatic and musculoskeletal diseases and adults with juvenile idiopathic arthritis: data from the EULAR COVAX physician-reported registry.
Lawson-Tovey S; Machado PM; Strangfeld A; Mateus E; Gossec L; Carmona L; Raffeiner B; Bulina I; Clemente D; Zepa J; Rodrigues AM; Mariette X; Hyrich KL;
RMD Open; 2022 Jul; 8(2):. PubMed ID: 35908834
[TBL] [Abstract][Full Text] [Related]
3. Predictors of Flare Following Etanercept Withdrawal in Patients with Rheumatoid Factor-negative Juvenile Idiopathic Arthritis Who Reached Remission while Taking Medication.
Aquilani A; Marafon DP; Marasco E; Nicolai R; Messia V; Perfetti F; Magni-Manzoni S; De Benedetti F
J Rheumatol; 2018 Jul; 45(7):956-961. PubMed ID: 29717035
[TBL] [Abstract][Full Text] [Related]
4. Leflunomide is associated with a higher flare rate compared to methotrexate in the treatment of chronic uveitis in juvenile idiopathic arthritis.
Bichler J; Benseler SM; Krumrey-Langkammerer M; Haas JP; Hügle B
Scand J Rheumatol; 2015; 44(4):280-3. PubMed ID: 25993023
[TBL] [Abstract][Full Text] [Related]
5. Treatment Withdrawal Following Remission in Juvenile Idiopathic Arthritis: A Systematic Review of the Literature.
Halyabar O; Mehta J; Ringold S; Rumsey DG; Horton DB
Paediatr Drugs; 2019 Dec; 21(6):469-492. PubMed ID: 31673960
[TBL] [Abstract][Full Text] [Related]
6. JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis.
Miserocchi E; Giuffrè C; Cornalba M; Pontikaki I; Cimaz R
Clin Rheumatol; 2020 Mar; 39(3):847-851. PubMed ID: 31897953
[TBL] [Abstract][Full Text] [Related]
7. Use of MRP8/14 in clinical practice as a predictor of outcome after methotrexate withdrawal in patients with juvenile idiopathic arthritis.
Sumner EJ; Almeida B; Palman J; Bale P; Heard C; Holzinger D; Roth J; Foell D; Robinson E; Ursu S; Wallace C; Gilmour K; Wedderburn LR; Ralph E
Clin Rheumatol; 2022 Sep; 41(9):2825-2830. PubMed ID: 35486225
[TBL] [Abstract][Full Text] [Related]
8. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
Shepherd J; Cooper K; Harris P; Picot J; Rose M
Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
[TBL] [Abstract][Full Text] [Related]
9. Treatment response to etanercept in methotrexate refractory juvenile idiopathic arthritis: an analysis of predictors and long-term outcomes.
Su Y; Yang YH; Chiang BL
Clin Rheumatol; 2017 Sep; 36(9):1997-2004. PubMed ID: 28540607
[TBL] [Abstract][Full Text] [Related]
10. Prevention of disease flares by risk-adapted stratification of therapy withdrawal in juvenile idiopathic arthritis: results from the PREVENT-JIA trial.
Gerss J; Tedy M; Klein A; Horneff G; Miranda-Garcia M; Kessel C; Holzinger D; Stanevica V; Swart JF; Cabral DA; Brunner HI; Foell D
Ann Rheum Dis; 2022 Jul; 81(7):990-997. PubMed ID: 35260388
[TBL] [Abstract][Full Text] [Related]
11. Re-treatment with etanercept is as effective as the initial firstline treatment in patients with juvenile idiopathic arthritis.
Klotsche J; Klein A; Niewerth M; Hoff P; Windschall D; Foeldvari I; Haas JP; Horneff G; Minden K
Arthritis Res Ther; 2021 Apr; 23(1):118. PubMed ID: 33863349
[TBL] [Abstract][Full Text] [Related]
12. A follow-up study of patients with juvenile idiopathic arthritis who discontinued etanercept due to disease remission.
Pratsidou-Gertsi P; Trachana M; Pardalos G; Kanakoudi-Tsakalidou F
Clin Exp Rheumatol; 2010; 28(6):919-22. PubMed ID: 21205467
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial.
Brunner HI; Ruperto N; Tzaribachev N; Horneff G; Chasnyk VG; Panaviene V; Abud-Mendoza C; Reiff A; Alexeeva E; Rubio-Pérez N; Keltsev V; Kingsbury DJ; Del Rocio Maldonado Velázquez M; Nikishina I; Silverman ED; Joos R; Smolewska E; Bandeira M; Minden K; van Royen-Kerkhof A; Emminger W; Foeldvari I; Lauwerys BR; Sztajnbok F; Gilmer KE; Xu Z; Leu JH; Kim L; Lamberth SL; Loza MJ; Lovell DJ; Martini A;
Ann Rheum Dis; 2018 Jan; 77(1):21-29. PubMed ID: 28507219
[TBL] [Abstract][Full Text] [Related]
14. Phagocyte-specific S100 proteins and high-sensitivity C reactive protein as biomarkers for a risk-adapted treatment to maintain remission in juvenile idiopathic arthritis: a comparative study.
Gerss J; Roth J; Holzinger D; Ruperto N; Wittkowski H; Frosch M; Wulffraat N; Wedderburn L; Stanevicha V; Mihaylova D; Harjacek M; Len C; Toppino C; Masi M; Minden K; Saurenmann T; Uziel Y; Vesely R; Apaz MT; Kuester RM; Elorduy MJ; Burgos-Vargas R; Ioseliani M; Magni-Manzoni S; Unsal E; Anton J; Balogh Z; Hagelberg S; Mazur-Zielinska H; Tauber T; Martini A; Foell D;
Ann Rheum Dis; 2012 Dec; 71(12):1991-7. PubMed ID: 22689317
[TBL] [Abstract][Full Text] [Related]
15. Predictors and long-term outcome in Greek adults with juvenile idiopathic arthritis: a 17-year continuous follow-up study.
Dimopoulou D; Trachana M; Pratsidou-Gertsi P; Sidiropoulos P; Kanakoudi-Tsakalidou F; Dimitroulas T; Garyfallos A
Rheumatology (Oxford); 2017 Nov; 56(11):1928-1938. PubMed ID: 29088453
[TBL] [Abstract][Full Text] [Related]
16. JAK inhibitors in the treatment of adult patients with juvenile idiopathic arthritis: a retrospective monocentric experience.
Chighizola CB; Pellico MR; Pandolfi M; Marelli L; Cornalba M; Pontikaki I; Costi S; Gattinara M; Marino A; Miserocchi E; Caporali R
Clin Exp Rheumatol; 2024 May; 42(5):974-982. PubMed ID: 38530666
[TBL] [Abstract][Full Text] [Related]
17. Treat to target (drug-free) inactive disease in DMARD-naive juvenile idiopathic arthritis: 24-month clinical outcomes of a three-armed randomised trial.
Hissink Muller P; Brinkman DMC; Schonenberg-Meinema D; van den Bosch WB; Koopman-Keemink Y; Brederije ICJ; Bekkering PW; Kuijpers TW; Van Rossum M; van Suijlekom-Smit LWA; van den Berg JM; Boehringer S; Allaart CF; Ten Cate R
Ann Rheum Dis; 2019 Jan; 78(1):51-59. PubMed ID: 30309970
[TBL] [Abstract][Full Text] [Related]
18. Early combination therapy with etanercept and methotrexate in JIA patients shortens the time to reach an inactive disease state and remission: results of a double-blind placebo-controlled trial.
Alexeeva E; Horneff G; Dvoryakovskaya T; Denisova R; Nikishina I; Zholobova E; Malievskiy V; Santalova G; Stadler E; Balykova L; Spivakovskiy Y; Kriulin I; Alshevskaya A; Moskalev A
Pediatr Rheumatol Online J; 2021 Jan; 19(1):5. PubMed ID: 33407590
[TBL] [Abstract][Full Text] [Related]
19. Disease Recapture Rates After Medication Discontinuation and Flare in Juvenile Idiopathic Arthritis: An Observational Study Within the Childhood Arthritis and Rheumatology Research Alliance Registry.
Ringold S; Dennos AC; Kimura Y; Beukelman T; Shrader P; Phillips TA; Kohlheim M; Schanberg LE; Yeung RSM; Horton DB;
Arthritis Care Res (Hoboken); 2023 Apr; 75(4):715-723. PubMed ID: 35921198
[TBL] [Abstract][Full Text] [Related]
20. Risk Factors and Biomarkers for the Occurrence of Uveitis in Juvenile Idiopathic Arthritis: Data From the Inception Cohort of Newly Diagnosed Patients With Juvenile Idiopathic Arthritis Study.
Tappeiner C; Klotsche J; Sengler C; Niewerth M; Liedmann I; Walscheid K; Lavric M; Foell D; Minden K; Heiligenhaus A
Arthritis Rheumatol; 2018 Oct; 70(10):1685-1694. PubMed ID: 29732713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
